Analystreport

Acasti Pharma Inc (NASDAQ: ACST) was downgraded by analysts at B. Riley to a "hold" rating. They now have a $2.00 price target on the stock.

Acasti Pharma, Inc. - Class A  (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors